Supernus Pharmaceuticals, Inc.
SUPN
$44.88
$1.563.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 64.50M | 61.91M | 73.87M | 59.71M | 5.24M |
| Total Depreciation and Amortization | 80.69M | 80.05M | 80.41M | 83.25M | 85.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | 0.00 | 0.00 |
| Total Other Non-Cash Items | 29.49M | 24.20M | 19.72M | 24.50M | 22.01M |
| Change in Net Operating Assets | 12.38M | -2.01M | -2.05M | 5.05M | 42.61M |
| Cash from Operations | 187.06M | 164.15M | 171.95M | 172.50M | 154.86M |
| Capital Expenditure | -1.20M | -804.00K | -725.00K | -476.00K | -426.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.74M | -100.12M | -189.14M | -242.73M | -131.14M |
| Cash from Investing | -82.94M | -100.93M | -189.87M | -243.21M | -131.57M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Common Stock | 15.66M | 14.04M | 14.91M | 9.12M | 6.40M |
| Repurchase of Common Stock | -4.76M | -4.72M | -2.72M | -1.73M | -2.31M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -22.40M | -20.10M | -- | -- | -- |
| Cash from Financing | -11.50M | -10.78M | 12.19M | 7.40M | 4.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.62M | 52.45M | -5.72M | -63.31M | 27.38M |